If you're an Apidra user, listen up!
Sanofi Aventis has announced that due to a technical malfunction at their plant in Frankfurt, Germany, production on all Apidra SoloSTAR insulin pens has come to a screeching halt. Sanofi has made it clear that this is an issue with the manufacturing of the pens themselves, not the insulin. Apidra insulin itself is running strong, and patients won't have issues with previously manufactured insulin pens or any vials of Apidra.
The pen shortage is expected to last until at least January 2012, possibly through the first quarter of next year. If you don't have enough pens in reserve, you'll need to talk to your doctor about switching to vials of Apidra.
Sanofi has set up a website to handle questions about the supply issue, with support resources and info about how to switch from pens to vials.
A pain in the rear for sure, but not the end of the world. We'll keep you in the loop as more updates come in.
NEWSFLASH: FDA Clears Dexcom Share Direct
Dexcom gets regulatory approval of its 'on-the-go' mobile apps for CGM data-sharing.
State of the Union: It's Time to Cure Diabetes
President launching new precision medicine initiative to better treat, cure diseases like diabetes.
'Robotic Pancreas' Appears On American Idol
Carlos Santana's nephew Adam Lasher shows off Dexcom G4 during live performance.